Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines has reported positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial. The trial evaluates ZIIHERA in combination with chemotherapy for treating HER2+ gastroesophageal adenocarcinoma. The findings reinforce the benefit of ZIIHERA-containing regimens as a first-line treatment option.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive topline results from Phase 3 HERIZON-GEA-01 trial.
  • ZIIHERA shows benefits in first-line treatment for HER2+ GEA.
  • Combination with chemotherapy and TEVIMBRA enhances treatment efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonst

Frequently Asked Questions

What is ZIIHERA used for?

ZIIHERA is used as a treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma.

What were the results of the Phase 3 trial?

The Phase 3 HERIZON-GEA-01 trial showed positive topline results for ZIIHERA in combination with chemotherapy.

What does the trial evaluate?

The trial evaluates ZIIHERA with and without TEVIMBRA as first-line treatment.

Who conducted the HERIZON-GEA-01 trial?

The trial was conducted by BeOne Medicines Ltd.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines ZIIHERA HER2+ cancer gastroesophageal adenocarcinoma Phase 3 trial
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →